Any surprises on the finalised terms of reference for the HTA review? The very clever politics of a 'supply only' arrangement and why the term 'commercial viability' confuses patients and masks the truth of changes that 'cut too deep'.
Latest Video
New Stories
-
The effort to change an institution from within, works best when exit is possible
October 15, 2026 - - Latest News -
The medicines gap costing Australian children time they can't get back
October 15, 2026 - - Latest News -
Brain cancer advocates return to Canberra 'to keep that ambition alive'
October 15, 2026 - - Latest News -
Priceline Pharmacy puts its name on the Diamonds as netball rides record growth
October 14, 2026 - - Latest News -
Until the law changes what the committee is instructed to weigh, these processes will deliver nothing
October 14, 2026 - - Latest News -
'Maximising off patent medicines and why the PBS needs a biosimilar strategy'
October 14, 2026 - - Latest News -
Peter Mac taps Sydney manufacturer to test its solid tumour CAR T therapy
October 14, 2026 - - Latest News
